Trial Profile

A Phase 1/2, Open-Label, Multicenter Study of INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCB 177054 (Primary) ; Retifanlimab (Primary)
Indications Head and neck cancer; Solid tumours
Focus Adverse reactions
Sponsors Incyte Corporation

Most Recent Events

02 Sep 2026 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: This was a strategic business decision. There were no safety concerns contributing to this decision.
16 Jun 2026 Planned End Date changed from 8 May 2026 to 30 Jul 2026.
16 Jun 2026 Planned primary completion date changed from 8 May 2026 to 30 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com